A Phase 1 interventional study of Lasmiditan and Propranolol in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-16.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the effects on heart rate and blood pressure when a single dose of lasmiditan is administered with a daily dose of propranolol. This study will also measure how much lasmiditan gets into the bloodstream after taking lasmiditan alone and after taking it together with propranolol. The study will also look at how well both drugs are tolerated. Information about any side effects that may occur will be collected.
This study will last approximately 45 days including screening. This study will require 13 days/12 nights in a Clinical Research Unit (CRU) followed by 1 follow-up appointment approximately 7 days after the last dose. Screening is required within 28 days prior to the start of the study.
This study is for research purposes only and is not intended to treat any medical condition.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
Drug: Lasmiditan
Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
Drug: Propranolol
Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
Drug: Lasmiditan · Drug: Propranolol
Administered orally
Also known as: LY573144
Administered orally
Change From Baseline (Day 8) in Mean Hourly Heart Rate Following Propranolol Administered Alone and When Coadministered With Lasmiditan
Change from baseline in mean hourly heart rate recorded as beats per minute and collected by Holter ambulatory monitoring in response to propranolol administered alone and in combination with lasmiditan.
Time frame: Baseline (Day 8), Day 9
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan Alone and When Coadministered With Propranolol
Maximum concentration of lasmiditan when administered alone on Day 1 and when coadministered with propranolol on Day 9.
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Pharmacokinetic: Maximum Observed Drug Concentration (Cmax) of Propranolol Alone and When Coadministered With Lasmiditan
Maximum concentration of propranolol when administered alone on Day 8 and when coadministered with lasmiditan on Day 9.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Last Measurable Concentration [AUC(0-tlast)] of Lasmiditan Alone and When Administered With Propranolol
AUC versus time curve (AUC 0-tlast) of lasmiditan when administered alone on Day 1 and when coadministered with propranolol on Day 9.
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose.
Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) of Propranolol During One Dosing Interval Alone and When Administered With Lasmiditan
AUC versus time curve of propranolol during one dosing interval when administered alone on Day 8 and when administered with lasmiditan on Day 9.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Change From Baseline (Day 8) in PR Interval Following Propranolol Administered Alone and When Coadministered With Lasmiditan
Change from baseline in PR interval, the interval between the P wave and the QRS complex calculated from electrocardiogram (ECG) data.
Time frame: Baseline (Day 8), Day 9
Change From Baseline (Day 8) in Systolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan
Change from baseline in systolic blood pressure was measured in supine position.
Time frame: Baseline (Day 8), Day 9
Change From Baseline (Day 8) in Diastolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan
Change from baseline in diastolic blood pressure was measured in supine position.
Time frame: Baseline (Day 8), Day 9
| Milestone | Lasmiditan (R); Propranolol (R) + Lasmiditan (T) |
|---|---|
| Started | 44 |
| Received at least one dose of study drug | 44 |
| Completed | 43 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
| Milestone | Lasmiditan (R); Propranolol (R) + Lasmiditan (T) |
|---|---|
| Started | 43 |
| Received at least one dose of study drug | 43 |
| Day 9 lasmiditan + propranolol test | 42 |
| Completed | 42 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Change from baseline in mean hourly heart rate recorded as beats per minute and collected by Holter ambulatory monitoring in response to propranolol administered alone and in combination with lasmiditan.
| beats per minute (bpm) | Propranolol (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Change From Baseline (Day 8) in Mean Hourly Heart Rate Following Propranolol Administered Alone and When Coadministered With Lasmiditan | 59.7 ± 7.1 | 54.2 ± 5.8 |
Maximum concentration of lasmiditan when administered alone on Day 1 and when coadministered with propranolol on Day 9.
| nanogram per mililiter (ng/mL) | Lasmiditan (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan Alone and When Coadministered With Propranolol | 323 ± 43 | 290 ± 31 |
Maximum concentration of propranolol when administered alone on Day 8 and when coadministered with lasmiditan on Day 9.
| ng/mL | Propranolol (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Pharmacokinetic: Maximum Observed Drug Concentration (Cmax) of Propranolol Alone and When Coadministered With Lasmiditan | 133 ± 52 | 127 ± 43 |
AUC versus time curve (AUC 0-tlast) of lasmiditan when administered alone on Day 1 and when coadministered with propranolol on Day 9.
| nanograms * hour/mL (ng*h/mL) | Lasmiditan (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Last Measurable Concentration [AUC(0-tlast)] of Lasmiditan Alone and When Administered With Propranolol | 2100 ± 39 | 2160 ± 30 |
AUC versus time curve of propranolol during one dosing interval when administered alone on Day 8 and when administered with lasmiditan on Day 9.
| ng*hr/mL | Propranolol (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) of Propranolol During One Dosing Interval Alone and When Administered With Lasmiditan | 910 ± 50 | 910 ± 43 |
Change from baseline in PR interval, the interval between the P wave and the QRS complex calculated from electrocardiogram (ECG) data.
| millisecond (msec) | Propranolol (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Change From Baseline (Day 8) in PR Interval Following Propranolol Administered Alone and When Coadministered With Lasmiditan | 165.6 ± 20.5 | 161.9 ± 20.3 |
Change from baseline in systolic blood pressure was measured in supine position.
| millimeters of mercury (mmHg) | Propranolol (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Change From Baseline (Day 8) in Systolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan | 106.9 ± 6.6 | 112.4 ± 10.9 |
Change from baseline in diastolic blood pressure was measured in supine position.
| mmHg | Propranolol (Reference Treatment) | Lasmiditan + Propranolol (Test Treatment) |
|---|---|---|
| Change From Baseline (Day 8) in Diastolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan | 64.0 ± 6.2 | 67.4 ± 7.8 |
Collected over Baseline through study completion (up to 23 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lasmiditan 200 mg (Reference Treatment) | 0/44 (0%) | 0/44 (0%) | 9/44 (20.5%) |
| Propranolol 80 mg (Reference Treatment) | 0/43 (0%) | 1/43 (2.3%) | 1/43 (2.3%) |
| Lasmiditan 200 mg + Propranolol 80 mg (Test Treatment) | 0/42 (0%) | 0/42 (0%) | 7/42 (16.7%) |
| Event | Lasmiditan 200 mg (Reference Treatment) | Propranolol 80 mg (Reference Treatment) | Lasmiditan 200 mg + Propranolol 80 mg (Test Treatment) |
|---|---|---|---|
| Anal abscessInfections and infestations | 0/44 | 1/43 | 0/42 |
| Event | Lasmiditan 200 mg (Reference Treatment) | Propranolol 80 mg (Reference Treatment) | Lasmiditan 200 mg + Propranolol 80 mg (Test Treatment) |
|---|---|---|---|
| DizzinessNervous system disorders | 6/44 | 1/43 | 4/42 |
| NauseaGastrointestinal disorders | 0/44 | 0/43 | 3/42 |
| FatigueGeneral disorders | 2/44 | 0/43 | 3/42 |
| ParaesthesiaNervous system disorders | 3/44 | 0/43 | 0/42 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Lasmiditan + Propranolol |
|---|---|
| Mean | 41.1 ± 12.8 |
| Sex: Female, Male(Participants) | Lasmiditan + Propranolol |
|---|---|
| Female | 12 |
| Male | 32 |
| Ethnicity (NIH/OMB)(Participants) | Lasmiditan + Propranolol |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lasmiditan + Propranolol |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 15 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | Lasmiditan + Propranolol |
|---|---|
| United States | 44 |
| Mean Hourly Heart Rate(beats per minute (BPM)) | Lasmiditan + Propranolol |
|---|---|
| Mean | 59.7 ± 7.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Nov 2017, 2 months.
Results were first posted in Dec 2019, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lasmiditan · Propranolol